How Much Weight Will You Actually Lose on GLP-1? Clinical Data Explained

"How much weight will I lose?" is the first question everyone asks about GLP-1 medications — and it deserves an honest, evidence-based answer. Not marketing claims. Not social media transformations. Clinical trial data.

→ For a complete overview, see our Complete Guide to GLP-1 Weight Loss in Hong Kong.

What the Clinical Trials Show

Three landmark trials provide the strongest evidence for GLP-1 weight-loss medications:

STEP 1: Semaglutide 2.4 mg (Injectable)

The STEP 1 trial enrolled 1,961 adults with BMI ≥30 (or ≥27 with at least one weight-related comorbidity) — without diabetes. All participants received lifestyle counselling (Wilding JPH et al. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185).

Results over 68 weeks: - Average weight loss: 14.9% (vs 2.4% with placebo) - 86.4% of participants lost ≥5% of body weight - 69.1% lost ≥10% - 50.5% lost ≥15% - 32.0% lost ≥20%

SURMOUNT-1: Tirzepatide (Mounjaro)

The SURMOUNT-1 trial tested tirzepatide at three doses (5 mg, 10 mg, 15 mg) in 2,539 adults with obesity — without diabetes (Jastreboff AM et al. N Engl J Med. 2022;387(3):205-216. PMID: 35658024).

Results over 72 weeks (15 mg dose): - Average weight loss: 22.5% (vs 3.1% with placebo) - 90.9% lost ≥5% - 78.9% lost ≥10% - 62.9% lost ≥15% - 47.4% lost ≥20%

SCALE: Liraglutide 3.0 mg (Saxenda)

The SCALE trial enrolled 3,731 adults with BMI ≥30 or ≥27 with comorbidities (Pi-Sunyer X et al. N Engl J Med. 2015;373(1):11-22. PMID: 26132939).

Results over 56 weeks: - Average weight loss: 8.0% (vs 2.6% with placebo) - 63.2% lost ≥5% - 33.1% lost ≥10%

What Do These Numbers Mean for You?

Let's translate percentages into real-world kilograms for different starting weights:

At 80 kg Starting Weight:

At 100 kg Starting Weight:

Important: These are averages. Individual results vary significantly — some patients lose much more, others less.

The Weight-Loss Timeline

Weight loss on GLP-1 medications doesn't happen overnight. Understanding the typical trajectory helps set realistic expectations:

Weeks 1–4: Dose Escalation Begins

• Appetite reduction is often noticeable within 1–2 weeks
• Weight loss is minimal at the lowest starting dose (0.25 mg semaglutide, 2.5 mg tirzepatide)
• GI side effects may be present as the body adjusts
• Expected: 1–2 kg

Weeks 4–12: Building Momentum

• Doses increase according to the escalation schedule
• Appetite suppression becomes more pronounced
• Consistent weight loss of 0.5–1.5 kg per week
• Expected: 4–8 kg total

Months 3–6: Peak Weight-Loss Phase

• Many patients reach their target or maintenance dose
• Weight loss continues at a steady rate
• Body composition changes become visible
• Expected: 8–15 kg total (varies by medication)

Months 6–12+: Plateau and Maintenance

• Rate of weight loss naturally slows
• Weight begins to stabilise at a new, lower set point
• Continued treatment maintains the loss
• Expected: 12–22 kg total at 12+ months

Factors That Influence Your Results

Factors Associated with Greater Weight Loss:

• Higher starting BMI(Based on clinical guidelines and prescribing information)
• Consistent medication adherence
• Concurrent dietary changes (reduced calorie intake, higher protein)
• Regular physical activity (especially resistance training)
• Adequate sleep (7–9 hours)
• No diabetes (patients with type 2 diabetes typically lose less weight on the same medications)(Based on clinical guidelines and prescribing information)

Factors That May Limit Results:

• Certain concurrent medications (some antidepressants, corticosteroids, insulin)(Based on clinical guidelines and prescribing information)
• Hormonal conditions (hypothyroidism, PCOS)(Based on clinical guidelines and prescribing information)
• Poor adherence to dosing schedule
• Inadequate dietary modification
• Sedentary lifestyle
• Genetics and metabolic factors

Clinical Trial vs Real-World Results

It's important to understand that clinical trial results represent ideal conditions: closely monitored patients, regular lifestyle counselling, and strict adherence protocols.

Real-world results are typically 10–20% lower than clinical trial averages(Based on clinical guidelines and prescribing information). This means: - Semaglutide real-world average: ~10–13% body weight - Tirzepatide real-world average: ~15–20% body weight - Liraglutide real-world average: ~5–7% body weight

These are still clinically significant and life-changing amounts of weight loss.

Beyond the Scale: Other Health Improvements

Weight loss is the most visible outcome, but GLP-1 medications also improve:

• Waist circumference: Reduced by an average of 10–15 cm in major trials(Based on clinical guidelines and prescribing information)
• Blood pressure: Systolic BP reduced by 3–6 mmHg on average(Based on clinical guidelines and prescribing information)
• Cholesterol: Improvements in LDL, triglycerides, and HDL ratios(Based on clinical guidelines and prescribing information)
• Blood sugar: HbA1c improvements even in non-diabetic patients(Based on clinical guidelines and prescribing information)
• Fatty liver: Reduction in liver fat content(Based on clinical guidelines and prescribing information)
• Sleep apnoea: Improvement in severity scores(Based on clinical guidelines and prescribing information)

These cardiometabolic improvements can occur even with modest weight loss (5–10%), making GLP-1 treatment worthwhile even if you don't reach the trial averages.

Setting Realistic Expectations

Here's what we tell patients at noah™:

1. 5% body weight loss is clinically meaningful — it improves metabolic health markers
2. 10% loss significantly reduces cardiovascular risk factors
3. 15%+ loss approaches results previously only achievable with bariatric surgery
4. Not everyone will be a "super responder" — and that's okay. A 10% loss is still excellent
5. The first 2–4 weeks may feel slow — the dose-escalation phase is necessary for tolerability

Frequently Asked Questions

1. What if I'm not losing weight after 3 months?

If you've been on a therapeutic dose for at least 8–12 weeks with minimal weight loss (<5%), your doctor may consider dose adjustment, switching medications, or investigating other contributing factors.

2. Will I lose muscle or just fat?

All weight-loss interventions result in some muscle loss. Studies suggest GLP-1 medications produce a ratio of approximately 60–75% fat loss to 25–40% lean mass loss(Based on clinical guidelines and prescribing information). Resistance training and adequate protein intake (1.2–1.6 g/kg/day) are crucial for preserving muscle.

3. Can I lose too much weight?

Yes, though this is uncommon. Your noah™ doctor monitors your progress and may reduce your dose if weight loss is excessive or too rapid. A healthy rate is generally 0.5–1 kg per week.

4. Do people with diabetes lose less weight?

Generally, yes. Clinical trials consistently show lower weight loss in patients with type 2 diabetes compared to those without, even on the same medication and dose(Based on clinical guidelines and prescribing information). This is thought to relate to insulin resistance and other metabolic factors.

5. How do GLP-1 results compare to bariatric surgery?

Bariatric surgery (gastric sleeve, bypass) typically produces 25–35% body weight loss(Based on clinical guidelines and prescribing information). Tirzepatide at the highest dose (22.5% average) approaches the lower end of surgical outcomes — a remarkable achievement for a medication.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. PMID: 33567185
2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024
3. Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373(1):11-22. PMID: 26132939

This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any medication. Treatment suitability is determined by your prescribing doctor based on your individual health profile.

© 2026 noah™. All rights reserved.